scholarly article | Q13442814 |
P50 | author | Brian J Zikmund-Fisher | Q40392300 |
Scott Roberts | Q88083206 | ||
Michele Gornick | Q88684063 | ||
P2093 | author name string | Arul M Chinnaiyan | |
Lan Q Le | |||
MI-ONCOSEQ Study team | |||
Natalie J Bartnik | |||
P2860 | cites work | A new initiative on precision medicine | Q29615654 |
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients | Q30591763 | ||
Quality of informed consent: a new measure of understanding among research subjects | Q33935042 | ||
Return of genomic results to research participants: the floor, the ceiling, and the choices in between | Q34000877 | ||
Communicating genetic and genomic information: health literacy and numeracy considerations | Q34017520 | ||
Personalized oncology through integrative high-throughput sequencing: a pilot study | Q34237470 | ||
Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics | Q34501849 | ||
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine | Q34526631 | ||
Have we asked too much of consent? | Q34598781 | ||
Effects of informed consent for individual genome sequencing on relevant knowledge | Q36312837 | ||
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth | Q36592140 | ||
Ethical issues with newborn screening in the genomics era | Q36761963 | ||
Development and clinical application of an integrative genomic approach to personalized cancer therapy | Q36954557 | ||
Harm, hype and evidence: ELSI research and policy guidance | Q36998724 | ||
Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine | Q37508612 | ||
Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. | Q38840660 | ||
The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. | Q42204343 | ||
Phase I oncology trials: why the therapeutic misconception will not go away | Q43245965 | ||
The Limits of Informed Consent for an Overwhelmed Patient: Clinicians' Role in Protecting Patients and Preventing Overwhelm | Q47389686 | ||
Integrative clinical genomics of metastatic cancer | Q48267403 | ||
When "Actionable" Genomic Sequencing Results Cannot Be Acted Upon. | Q50145151 | ||
Understanding the 'therapeutic misconception' from the research participant's perspective | Q50213573 | ||
Validation of a decision regret scale | Q51019738 | ||
Value-based genomics. | Q55339672 | ||
The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results | Q57907556 | ||
Toward greater understanding of patient decision-making around genome sequencing | Q88528819 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 227-237 | |
P577 | publication date | 2019-01-01 | |
P1433 | published in | Cancer Medicine | Q27724564 |
P1476 | title | Next-generation sequencing in precision oncology: Patient understanding and expectations | |
P478 | volume | 8 |
Q92187870 | Implementation of Precision Cancer Medicine: Progress and the Path to Realizing the Promise of Tumor Sequencing |
Q94585065 | Metastatic breast cancer patient perceptions of somatic tumor genomic testing |
Q90223268 | Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population |
Q92947776 | The Future of Precision Oncology for the Treatment of Solid Tumors |
Search more.